Welcome to our dedicated page for Corbus Pharmaceuticals Holdings news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company dedicated to creating innovative therapies for rare, chronic, and serious inflammatory and fibrotic diseases. The company's leading product candidate, Resunab™, is a pioneering oral anti-inflammatory drug designed to resolve inflammation through an endogenous pathway. Resunab™ is set to begin three Phase 2 clinical trials in 2015 targeting cystic fibrosis, diffuse systemic sclerosis (scleroderma), and dermatomyositis, all conditions where inflammation significantly contributes to disease progression. Additionally, Resunab™ has the potential to address other rare inflammatory diseases.
Corbus Pharmaceuticals is also a precision oncology company with a diversified portfolio aimed at tackling serious illnesses using scientific approaches to well-known biological pathways. The company's development pipeline includes several key candidates:
- CRB-701: A next-generation antibody-drug conjugate (ADC) targeting Nectin-4 on cancer cells, releasing a cytotoxic payload.
- CRB-601: An anti-integrin monoclonal antibody blocking TGFβ activation expressed on cancer cells.
- CRB-913: A second-generation, peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Recent developments include the FDA clearance of CRB-601 for a Phase 1 study expected to enroll the first patient in the summer of 2024. Additionally, the company completed a public offering in February 2024, raising $94.5 million, and reported $127 million in cash, cash equivalents, and investments as of February 2, 2024, extending their cash runway through March 31, 2027.
Corbus aims to use the net proceeds from their recent underwritten offering to further their clinical development pipeline, ensuring robust progress across their range of innovative therapies. The company's partnerships and collaborations, such as with CSPC Pharmaceutical Group, highlight their commitment to advancing their pipeline and translating scientific discoveries into effective treatments for patients worldwide.
Headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals is at the forefront of the biotechnology field, continuously striving to bring first-in-class treatments to market, thereby addressing unmet medical needs and improving patient outcomes. For more information, visit corbuspharma.com.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is set to host a virtual 'Meet the Expert' event on April 25, 2023, at 11:00 AM ET. The focus will be on CRB-601, an anti-integrin monoclonal antibody targeting Transforming Growth Factor β (TGFβ) in oncology. Featuring notable researchers Dr. Jeffrey Clarke and Dr. Joan Seoane, the session will highlight CRB-601's potential to inhibit tumor growth, as evidenced in non-clinical studies. The company plans to submit an Investigational New Drug (IND) application for CRB-601 in the latter half of 2023. This initiative underscores Corbus's commitment to advancing precision oncology by innovating treatments for serious illnesses.
Corbus Pharmaceuticals (NASDAQ: CRBP) recently showcased promising pre-clinical data for its drug CRB-601 at the 2023 AACR annual meeting. The study revealed that CRB-601, an avβ8 blocking antibody, demonstrated dose-dependent antitumor activity and significantly enhanced the efficacy of anti-PD-1 immunotherapy. Additionally, the IND submission for CRB-601 is on track for the second half of 2023. The findings highlighted a notable increase in immune cell populations within tumors, along with a blockade of the TGFβ signaling pathway. The combination therapy showed substantial tumor growth inhibition in pre-clinical models, suggesting a strong potential for CRB-601 in cancer treatment.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that pre-clinical data for its avβ8 blocking antibody, CRB-601, has been accepted for presentation at the 2023 American Association for Cancer Research annual meeting in Orlando, FL, from April 14-19, 2023.
The poster presentation is titled CRB-601, an avβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment and will occur on April 16, 2023, from 1:30 PM - 5:00 PM.
Corbus focuses on innovative treatments targeting well-understood biological pathways in cancer therapy.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has announced significant advancements in its precision oncology pipeline, highlighted by the exclusive licensing of CRB-701, a next-generation Nectin-4 antibody-drug conjugate. CRB-701 is currently in Phase 1 trials in China, targeting advanced solid tumors. Additionally, the company is on track for an IND submission of CRB-601 in late 2023, showcasing promising pre-clinical data. Financially, Corbus reported a net loss of approximately $10.9 million for Q4 2022, slightly worsening from the previous year. Despite these losses, the company maintains $59.2 million in cash, sufficient to fund operations into mid-2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the appointment of Yong Ben, M.D., MBA, to its Board of Directors on March 6, 2023. Dr. Ben brings over 20 years of oncology experience, having led numerous clinical development programs, including drug approvals at renowned companies. His expertise in healthcare venture investment is expected to enhance Corbus' strategic capabilities. The company's recent license agreement for CRB-701 bolsters its position in precision oncology. Corbus aims to advance its pipeline, including CRB-701 and CRB-601, under Dr. Ben's guidance.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will present a corporate update and engage in one-on-one investor meetings at the Oppenheimer 33rd Annual Healthcare Conference, hosted virtually from March 13-15, 2023.
The presentation is scheduled for March 14, 2023, at 9:20 a.m. ET. Investors can access the webcast here.
Corbus focuses on precision oncology, with key products including CRB-701 and CRB-601 targeting cancer cells.
Corbus Pharmaceuticals Holdings has entered an exclusive licensing agreement with CSPC Pharmaceutical Group for the development of CRB-701, an antibody drug conjugate targeting Nectin-4. This drug is being developed for various cancers, including urothelial, lung, breast, and prostate. An upfront payment of $7.5 million will be made to CSPC, with potential milestone payments totaling $685 million. The agreement also includes a 1-for-30 reverse stock split effective February 14, 2023, aimed at maintaining compliance with Nasdaq's minimum bid price requirement of $1.00. Corbus aims to initiate US clinical trials in 2024.
FAQ
What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?
What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?
What diseases does Corbus Pharmaceuticals target?
What is Resunab™?
What are the key products in Corbus’ development pipeline?
Where is Corbus Pharmaceuticals headquartered?
What recent financial developments has Corbus Pharmaceuticals announced?
Who are Corbus Pharmaceuticals’ partners?
When is Corbus Pharmaceuticals expected to begin the Phase 1 study of CRB-601?
What is the focus of CRB-701?
What is the purpose of the recent underwritten offering by Corbus Pharmaceuticals?
How can potential investors learn more about Corbus Pharmaceuticals' offerings?
